These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26766804)

  • 21. Effects of 5-alpha reductase inhibitors on erectile function, sexual desire and ejaculation.
    Gur S; Kadowitz PJ; Hellstrom WJ
    Expert Opin Drug Saf; 2013 Jan; 12(1):81-90. PubMed ID: 23173718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-finasteride syndrome: a surmountable challenge for clinicians.
    Traish AM
    Fertil Steril; 2020 Jan; 113(1):21-50. PubMed ID: 32033719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
    Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
    JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate, baldness drugs linked to sexual dysfunction.
    Kuehn BM
    JAMA; 2012 May; 307(18):1903. PubMed ID: 22570451
    [No Abstract]   [Full Text] [Related]  

  • 25. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
    Azoulay L; Eberg M; Benayoun S; Pollak M
    JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
    Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction?
    Lynn R; Krunic A
    Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety.
    Dhurat R; Sharma A; Rudnicka L; Kroumpouzos G; Kassir M; Galadari H; Wollina U; Lotti T; Golubovic M; Binic I; Grabbe S; Goldust M
    Dermatol Ther; 2020 May; 33(3):e13379. PubMed ID: 32279398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sexual dysfunction with 5-alpha-reductase inhibitor therapy for androgenetic alopecia: A global propensity score matched retrospective cohort study.
    Lauck KC; Limmer A; Harris P; Kivelevitch D
    J Am Acad Dermatol; 2024 Jul; 91(1):163-166. PubMed ID: 38552905
    [No Abstract]   [Full Text] [Related]  

  • 30. Long-term safety and efficacy of dutasteride in the treatment of male patients with androgenetic alopecia.
    Tsunemi Y; Irisawa R; Yoshiie H; Brotherton B; Ito H; Tsuboi R; Kawashima M; Manyak M;
    J Dermatol; 2016 Sep; 43(9):1051-8. PubMed ID: 26893187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgenetic alopecia; drug safety and therapeutic strategies.
    Motofei IG; Rowland DL; Baconi DL; Tampa M; Sârbu MI; Păunică S; Constantin VD; Bălălău C; Păunică I; Georgescu SR
    Expert Opin Drug Saf; 2018 Apr; 17(4):407-412. PubMed ID: 29363345
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5α-Reductase inhibitors in men aged 50 years or older with androgenetic alopecia: A retrospective study.
    Kang MJ; Choi JY; Sim WY; Lew BL
    J Am Acad Dermatol; 2021 Jan; 84(1):172-173. PubMed ID: 32320771
    [No Abstract]   [Full Text] [Related]  

  • 33. The Cardiovascular Safety of Dutasteride.
    Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
    J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date.
    Iamsumang W; Leerunyakul K; Suchonwanit P
    Drug Des Devel Ther; 2020; 14():951-959. PubMed ID: 32184564
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of Depression Associated With Finasteride Treatment.
    Pompili M; Magistri C; Maddalena S; Mellini C; Persechino S; Baldessarini RJ
    J Clin Psychopharmacol; 2021 May-Jun 01; 41(3):304-309. PubMed ID: 33814544
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia.
    Tsai TF; Choi GS; Kim BJ; Kim MB; Ng CF; Kochhar P; Jasper S; Brotherton B; Orban B; Lulic Z
    J Dermatol; 2018 Jul; 45(7):799-804. PubMed ID: 29667763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Finasteride Use Is Associated with Higher Odds of Obstructive Sleep Apnea: Results from the US Food and Drug Administration Adverse Events Reporting System.
    Gupta MA; Vujcic B; Gupta AK
    Skinmed; 2020; 18(3):146-150. PubMed ID: 32790610
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Re: inhibitors of 5α-reductase-related side effects in patients seeking medical care for sexual dysfunction.
    Kaplan SA
    J Urol; 2014 Mar; 191(3):752. PubMed ID: 24522062
    [No Abstract]   [Full Text] [Related]  

  • 40. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis.
    Zhou Z; Song S; Gao Z; Wu J; Ma J; Cui Y
    Clin Interv Aging; 2019; 14():399-406. PubMed ID: 30863034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.